topotecan has been researched along with Melanoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaria, R; Ashkin, E; Bernatchez, C; Chen, Y; Davis, RE; Devi, S; Forget, MA; Haymaker, C; Heffernan, T; Hu, J; Huang, L; Hwu, P; Kalra, A; Liu, C; Malu, S; Mbofung, RM; McKenzie, JA; Muller, F; Peng, W; Pradeep, S; Roszik, J; Satani, N; Sood, A; Tieu, T; Williams, L; Xu, C; Zhang, M; Zorro Manrique, S | 1 |
| Animati, F; Bellarosa, D; Bigioni, M; Binaschi, M; Bressan, A; Bugianesi, R; Crea, A; Maggi, CA; Manzini, S; Parlani, M; Rivoltini, L | 1 |
| de Lange, J; Jager, MJ; Jochemsen, AG; Lodder, K; Ly, LV; Teunisse, AF; Verlaan-de Vries, M | 1 |
| Ju, RJ; Li, N; Li, RJ; Lu, WL; Wang, XX; Wang, ZH; Yao, HJ; Yu, Y; Zhang, L; Zhang, Y; Zhou, J | 1 |
| Binda, M; Citti, L; Daidone, MG; De Cesare, M; Folini, M; Pennati, M; Pratesi, G; Zaffaroni, N; Zunino, F | 1 |
| Kraut, E; Muller, MT; Staubus, A; Subramanian, D; Young, DC | 1 |
| Caserini, C; Orlandi, L; Silvestrini, R; Supino, R; Vaglini, M; Zaffaroni, N; Zunino, F | 1 |
| Boothman, DA; Kinsella, TJ; Lamond, JP; Wang, M | 1 |
| Balcerzak, SP; Gochnour, D; Kraut, EH; Staubus, A; Walker, MJ | 1 |
| Conlon, KC; Curti, BD; Gause, BL; Janik, JE; Korn, EL; Longo, DL; Miller, LL; Sharfman, W; Smith, JW; Stevens, D; Sznol, M; Urba, WJ | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
1 review(s) available for topotecan and Melanoma
| Article | Year |
|---|---|
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
4 trial(s) available for topotecan and Melanoma
| Article | Year |
|---|---|
Analysis of topoisomerase I/DNA complexes in patients administered topotecan.
Topics: Antineoplastic Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; HeLa Cells; Humans; Lymphoma, Non-Hodgkin; Melanoma; Topotecan | 1995 |
Phase II trial of topotecan in malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Topotecan | 1997 |
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2001 |
7 other study(ies) available for topotecan and Melanoma
| Article | Year |
|---|---|
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
Topics: Animals; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Immunotherapy, Adoptive; Irinotecan; Lymphocytes, Tumor-Infiltrating; Melanoma; Mice; Mice, Inbred C57BL; T-Lymphocytes, Cytotoxic; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dextrans; Female; Humans; Leukemia, Myeloid; Macrophages; Melanoma; Mice; Mice, Nude; Ovarian Neoplasms; Tissue Distribution; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Synergism; Furans; Humans; Hypoxia; Imidazoles; Melanoma; Melanoma, Experimental; Mice; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Topotecan; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uveal Neoplasms | 2012 |
Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liposomes; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Skin Neoplasms; Topotecan | 2012 |
Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 9; Caspases; Down-Regulation; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Melanoma; Mice; Microtubule-Associated Proteins; Neoplasm Proteins; RNA, Catalytic; Survivin; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous | 2004 |
Modulation of melphalan cytotoxic activity in human melanoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Blotting, Northern; Camptothecin; Drug Interactions; Enzyme Inhibitors; Ethacrynic Acid; Humans; Melanoma; Melphalan; Temperature; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Combined Modality Therapy; Fibroblasts; Humans; Melanoma; Neoplasms; Radiation Dosage; Radiation Tolerance; Time Factors; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |